About
Technology
Issues
FAQ
Title
Abstract
Text
Figure Captions
Table Cells
Section Titles
Keywords
Subjects
Authors
From
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
2004
2003
2002
2001
2000
1995
1990
1985
1980
1975
1970
1960
1950
1940
1930
1920
1910
1900
1850
1800
1700
1600
To
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
2004
2003
2002
2001
2000
1995
1990
1985
1980
1975
1970
1960
1950
1940
1930
1920
1910
1900
1850
1800
1700
1600
All Types
Articles
Communications
Reviews
Discussions
Case Reports
Chapters
Books
News
Editorials
Order By
Order By Year ASC
Order By Year DESC
Order By Citations ASC
Order By Citations DESC
Go
Scientometrics
Impact Factor
Discipline Ranks
H-Index
G-Index
Articles
Citations
Article Citations
Citation Distribution
Search This Journal
Overviews
Top Institutions
Top Schools
Top Authors
Prolific Authors
Top Articles
exaly
›
Journals
›
Clinical Breast Cancer
›
Top Articles
Clinical Breast Cancer
Oncology
3
(top 5%)
Impact Factor
3.3
(top 5%)
extended IF
72
(top 5%)
H-Index
1.7K
authors
2.1K
papers
35.5K
citations
3.5K
citing journals
21.5K
citing authors
Most Cited Articles of Clinical Breast Cancer
Title
Year
Citations
HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues
2004
504
Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer
2009
424
The global breast cancer burden: variations in epidemiology and survival
2005
346
Survival outcomes for patients with metastatic triple-negative breast cancer: implications for clinical practice and trial design
2009
303
Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab
2005
296
TAILORx: trial assigning individualized options for treatment (Rx)
2006
217
Insulin-lowering effects of metformin in women with early breast cancer
2008
191
Cognitive training for improving executive function in chemotherapy-treated breast cancer survivors
2013
179
Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results
2009
174
Stress Management and Resilience Training (SMART) program to decrease stress and enhance resilience among breast cancer survivors: a pilot randomized clinical trial
2011
169
Phase II study of weekly albumin-bound paclitaxel for patients with metastatic breast cancer heavily pretreated with taxanes
2007
144
Classification, Treatment Strategy, and Associated Drug Resistance in Breast Cancer
2016
142
Molecular mechanisms of breast cancer metastases to bone
2005
139
Neoadjuvant docetaxel in breast cancer: 3-year survival results from the Aberdeen trial
2002
135
Metastasis suppressor genes: basic biology and potential clinical use
2003
130
Serum interleukin 6, plasma VEGF, serum VEGF, and VEGF platelet load in breast cancer patients
2002
127
The cathepsin K inhibitor odanacatib suppresses bone resorption in women with breast cancer and established bone metastases: results of a 4-week, double-blind, randomized, controlled trial
2010
119
Results of a diet/exercise feasibility trial to prevent adverse body composition change in breast cancer patients on adjuvant chemotherapy
2008
119
Basal breast cancer molecular subtype predicts for lower incidence of axillary lymph node metastases in primary breast cancer
2008
118
Two concurrent phase II trials of paclitaxel/carboplatin/trastuzumab (weekly or every-3-week schedule) as first-line therapy in women with HER2-overexpressing metastatic breast cancer: NCCTG study 983252
2005
118
Breast cancer chemotherapy-related cognitive dysfunction
2002
116
Circulating Tumor Cells in Metastatic Breast Cancer: Biologic Staging Beyond Tumor Burden
2007
115
Peripheral neuropathy with microtubule-targeting agents: occurrence and management approach
2011
114
Incidence and patterns of distant metastases for patients with early-stage breast cancer after breast conservation treatment
2013
113
Mammalian target of rapamycin: a new molecular target for breast cancer
2003
111
0
1
2
next
How are inpact factors calculated?
The impact factor (IF) is calculated by counting citations from peer-reviewed journals only.
extended IF
also counts citations from books and conference papers. However, no patent, abstract, working papers, online documents, etc., are covered.
site/software ©
exaly
; All materials licenced under
CC by-SA
.